PharmaCyte shareholders approve authorized share increase to 200M and financing-related issuance

the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Articles of Incorporation, as amended (the “Charter”), to increase the total number of authorized shares of the Company’s common stock from 133,333,334 to 200,000,000. On September 6, 2023, the Company filed the Amendment with the Secretary of State of the State of Nevada with immediate effect.

Proposal 2. Approval of the Increase of Authorized Shares of Common Stock. The approval of an amendment to the Charter to increase the total number of authorized shares of common stock from 133,333,334 to 200,000,000: For Against Abstain 9,982,019 1,019,080 421,264

Proposal 1. Authorization of the Issuance of Shares. The authorization, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of shares of the Company’s common stock underlying shares of convertible preferred stock and warrants issued by the Company pursuant to the terms of that certain Securities Purchase Agreement, dated May 9, 2023, by and between the Company and the investors named therein, in an amount equal to or in excess of 20% of the Company’s common stock outstanding before the issuance of such convertible preferred stock and warrants (including any amortization payments made to the holders of convertible preferred stock in the form of issuance of shares of common stock and upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants): For Against Abstain Broker Non-Votes 7,170,025 400,161 432,796 3,419,381